September 8, 2021
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing …
Updates
May 3, 2021
CaaMTech CEO Chadeayne to Speak at 2021 Psychedelic Therapeutics & Drug Development Conference
Dr. Andrew Chadeayne will speak about filling the unmet need for pure, well-characterized tryptamines
April 13, 2021
CaaMTech Furthers 5-MeO-DMT Research with Orally Active 5-MeO-DPT
5-MeO-DPT is a structural analog of 5-MeO-DMT, the “God molecule”
March 22, 2021
CaaMTech Synthesizes Water-Soluble ‘Foxtrot’ Salt
5-MeO-DALT fumarate is the latest novel compound from CaaMTech and UMass Dartmouth’s Manke Lab
March 10, 2021
USPTO Publishes “Alkyl Quaternary Ammonium Tryptamines and Their Therapeutic Uses”
CaaMTech’s latest published patent application covers important, yet understudied tryptamine compounds
February 10, 2021
Patent Combining Psychedelics with Cannabinoids Allowed by USPTO
CaaMTech’s first of over one hundred patent applications is nearing the finish line
February 5, 2021
Can Synthetic Bufotenidinium Save the Toads?
CaaMTech’s synthesizes another important Bufo alvarius toad secretion compound
January 29, 2021
CaaMTech Synthesizes New Psychedelic Toad Derivatives
5-MeO-2-Me-DMT fumarate and 5-MeO-2-Me-TMT iodide, are novel salts structurally similar to the psychoactive tryptamines found in the secretions of Bufo alvarius toads
January 11, 2021
CaaMTech Synthesizes 3 More Psilocybin Alternatives
CaaMTech’s latest paper puts the spotlight on three novel psilocin prodrugs: 4-AcO-MET hydrofumarate, 4-AcO-MALT hydrofumarate & 4-AcO-DALT fumarate
December 9, 2020
CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth
The Manke Lab at UMass Dartmouth is a global leader in novel tryptamine synthesis and characterization
